Manufacturing
CDMO Pulse Check: Lonza Posts Major Sales Rebound as Samsung Bio Keeps Revenue Growth Rolling
Lonza; CDMO; sales growth; Samsung Bio; 2025 outlook; profit margin; Capsules & Health Ingredients; commercial momentum; manufacturing expansion
AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia
AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals
Biogen Pledges $2 Billion Manufacturing Investment in North Carolina
Biogen; manufacturing investment; North Carolina; Research Triangle Park; biotechnology; antisense oligonucleotides; gene therapy; automation; AI; expansion
Big Pharma Braces for Potential 200% US Tariffs Amid Uncertainty
pharmaceutical industry; tariffs; Donald Trump; supply chains; onshoring; drug prices; manufacturing; healthcare system
UCB Announces Major Investment to Expand US Biologics Manufacturing Capacity
UCB; biologics manufacturing; US expansion; biomanufacturing; biopharmaceutical; investment; jobs; economic impact
New Rules and Regulatory Trends in Biopharma Manufacturing in 2025
biopharma manufacturing; 2025 regulations; FDA; digital quality systems; green manufacturing; import rules; Trump administration tariffs; country-of-origin labeling; forced labor compliance; serialization
National Resilience Restructures Manufacturing Footprint, Closes 6 of 10 Plants
National Resilience; manufacturing; CDMO; restructuring; overcapacity; biotech
Schott Pharma Invests Over €100M in New Sterile Cartridge Facility at Hungary Site
Schott Pharma; Hungary; sterile cartridge facility; €100 million investment; RTU cartridges; pharma packaging; manufacturing expansion; Lukácsháza; GLP-1 drugs; diabetes; automation; environmental impact
‘Go ahead and do it’: Top RFK Jr. Deputy Dares Drugmakers Over Threats to Pull Manufacturing Amid Price Pressure
RFK Jr.; drug pricing; Calley Means; HHS; pharmaceutical industry; manufacturing threats; Roche; executive order; price limits; Big Pharma
Sanofi Commits $20 Billion to U.S. R&D and Manufacturing by 2030
Sanofi; $20 billion investment; U.S. manufacturing; R&D; job creation; drug launches; domestic partnerships